中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

101 records (took 0.06 seconds)

    Use of inactive immunosuppressive and/or angiogenic immunogenic proteins, for producing secretory IgA's
    11.
    发明授权
    Use of inactive immunosuppressive and/or angiogenic immunogenic proteins, for producing secretory IgA's 有权
    使用无活性免疫抑制和/或血管生成免疫原性蛋白，用于产生分泌型IgA

    公开(公告)号：US07351554B2

    公开(公告)日：2008-04-01

    申请号：US11302286

    申请日：2005-12-14

    Applicant: Daniel Zagury

    Inventor： Daniel Zagury

    IPC: C12P21/06

    CPC classification number: C07K16/18 ,  A61K9/0043 ,  A61K39/12 ,  A61K39/21 ,  A61K2039/505 ,  A61K2039/53 ,  A61K2039/541 ,  A61K2039/542 ,  A61K2039/543 ,  A61K2039/545 ,  A61K2039/55505 ,  A61K2039/55544 ,  A61K2039/55566 ,  A61K2039/585 ,  C07K16/1036 ,  C07K16/1063 ,  C12N2740/16034 ,  C12N2740/16134 ,  C12N2740/16334

    Abstract: A method for inducing a mucosal immunity with production of secretory IgA antibodies that neutralize of block a native E7 protein originating from cancerous cells, from cells infected by a human Papillomavirus or from an immune system cell. The method includes administering to a patient in need thereof, a vaccine composition containing an active compound which is the native E7 protein, the properties of which have been inactivated by at least 70% by a physical and/or a chemical treatment, by genetic recombination or by adjuvant conditions; an inactive fragment of the immunosuppressive and/or angiogenic native E7 protein; a DNA molecule encoding the immunosuppressive and/or angiogenic native E7 protein inactivated by at least 70% by mutation; or a DNA molecule encoding an inactive fragment of the immunosuppressive and/or angiogenic native E7 protein; along with an adjuvant of mucosal immunity.

    Abstract translation: 一种产生分泌型IgA抗体诱导粘膜免疫的方法，其中和阻断源自癌细胞的天然E7蛋白，来自人乳头瘤病毒感染的细胞或免疫系统细胞。 该方法包括向有需要的患者施用含有天然E7蛋白的活性化合物的疫苗组合物，其性质通过物理和/或化学处理通过遗传重组已被灭活至少70％ 或通过辅助条件; 免疫抑制和/或血管生成天然E7蛋白的无活性片段; 编码通过突变至少70％灭活的免疫抑制和/或血管生成天然E7蛋白质的DNA分子; 或编码免疫抑制和/或血管生成天然E7蛋白的无活性片段的DNA分子; 以及粘膜免疫佐剂。

    Use of inactive immunosuppressive and/or angiogenic immunogenic proteins, for producing secretory IgA's
    12.
    发明申请
    Use of inactive immunosuppressive and/or angiogenic immunogenic proteins, for producing secretory IgA's 有权
    使用无活性免疫抑制和/或血管生成免疫原性蛋白，用于产生分泌型IgA

    公开(公告)号：US20060153863A1

    公开(公告)日：2006-07-13

    申请号：US11302286

    申请日：2005-12-14

    Applicant: Daniel Zagury

    Inventor： Daniel Zagury

    IPC: A61K39/12

    CPC classification number: C07K16/18 ,  A61K9/0043 ,  A61K39/12 ,  A61K39/21 ,  A61K2039/505 ,  A61K2039/53 ,  A61K2039/541 ,  A61K2039/542 ,  A61K2039/543 ,  A61K2039/545 ,  A61K2039/55505 ,  A61K2039/55544 ,  A61K2039/55566 ,  A61K2039/585 ,  C07K16/1036 ,  C07K16/1063 ,  C12N2740/16034 ,  C12N2740/16134 ,  C12N2740/16334

    Abstract: A method for inducing a mucosal immunity with production of secretory IgA antibodies that neutralize of block a native E7 protein originating from cancerous cells, from cells infected by a human Papillomavirus or from an immune system cell. The method includes administering to a patient in need thereof, a vaccine composition containing an active compound which is the native E7 protein, the properties of which have been inactivated by at least 70% by a physical and/or a chemical treatment, by genetic recombination or by adjuvant conditions; an inactive fragment of the immunosuppressive and/or angiogenic native E7 protein; a DNA molecule encoding the immunosuppressive and/or angiogenic native E7 protein inactivated by at least 70% by mutation; or a DNA molecule encoding an inactive fragment of the immunosuppressive and/or angiogenic native E7 protein; along with an adjuvant of mucosal immunity.

    Abstract translation: 一种产生分泌型IgA抗体诱导粘膜免疫的方法，其中和阻断源自癌细胞的天然E7蛋白，来自人乳头瘤病毒感染的细胞或免疫系统细胞。 该方法包括向有需要的患者施用含有天然E7蛋白的活性化合物的疫苗组合物，其性质通过物理和/或化学处理通过遗传重组已被灭活至少70％ 或通过辅助条件; 免疫抑制和/或血管生成天然E7蛋白的无活性片段; 编码通过突变至少70％灭活的免疫抑制和/或血管生成天然E7蛋白质的DNA分子; 或编码免疫抑制和/或血管生成天然E7蛋白的无活性片段的DNA分子; 以及粘膜免疫佐剂。

    Intracellular antibodies for a retrovirus protein
    13.
    发明申请
    Intracellular antibodies for a retrovirus protein 审中-公开
    逆转录病毒蛋白的细胞内抗体

    公开(公告)号：US20060150261A1

    公开(公告)日：2006-07-06

    申请号：US11372250

    申请日：2006-03-09

    Applicant: Dubravka Drabek ,  Sylvia Dekker ,  Franklin Grosveld

    Inventor： Dubravka Drabek ,  Sylvia Dekker ,  Franklin Grosveld

    IPC: A01K67/027

    CPC classification number: C07K16/40 ,  A01K2217/05 ,  A01K2267/01 ,  C07K16/1036 ,  C07K2317/22 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/80

    Abstract: A transgenic organism is provided comprising a polynucleotide construct encoding an intracellular antibody which disrupts the catalysis of the production of the xenoantigen galactose α 1,3 galactose and/or a polynucleotide construct which encodes an intracellular antibody which binds specifically to a retrovirus protein, such as a PERV particle protein. Also described are methods for the production of such organisms. Cells, tissues and organs of the transgenic organism may be used in xenotransplantation.

    Abstract translation: 提供了一种转基因生物体，其包含编码细胞内抗体的多核苷酸构建体，该多核苷酸构建体破坏了异种人抗原半乳糖α1,3半乳糖的产生的催化和/或编码与抗逆转录病毒蛋白特异性结合的细胞内抗体的多核苷酸构建体，例如 PERV颗粒蛋白。 还描述了生产这种生物体的方法。 转基因生物的细胞，组织和器官可用于异种移植。

    Use of inactivated immunosuppressive or angiogenic immunogenic proteins for producing secretory iga's
    14.
    发明申请
    Use of inactivated immunosuppressive or angiogenic immunogenic proteins for producing secretory iga's 有权
    使用灭活的免疫抑制或血管发生免疫原性蛋白来产生分泌型iga

    公开(公告)号：US20030003106A1

    公开(公告)日：2003-01-02

    申请号：US10168115

    申请日：2002-06-17

    Inventor： Daniel Zagury

    IPC: A61K039/00 ,  A61K048/00

    CPC classification number: C07K16/18 ,  A61K9/0043 ,  A61K39/12 ,  A61K39/21 ,  A61K2039/505 ,  A61K2039/53 ,  A61K2039/541 ,  A61K2039/542 ,  A61K2039/543 ,  A61K2039/545 ,  A61K2039/55505 ,  A61K2039/55544 ,  A61K2039/55566 ,  A61K2039/585 ,  C07K16/1036 ,  C07K16/1063 ,  C12N2740/16034 ,  C12N2740/16134 ,  C12N2740/16334

    Abstract: The invention concerns the use of a protein derived from cancel cells, cells infected by a virus or immune cells or an inactive fragment of said protein, said protein being initially an immunosuppressive and/or an angiogenic protein with local activity whereof said properties have been inactivated by at least 70% by a physical and/or chemical treatment, such as formolisation, carboxamidation, carboxymethylation, maleimidation or oxidation by oxygen bubbling, by genetic recombination or by adjuvant conditioning, said treatment preserving its property of being identified by antibodies directed against said protein, and preserving sufficient immunogenic properties for generating antibodies neutralizing or blocking said native protein, or the use of a DNA molecule corresponding to said protein inactivated by mutation or to said inactive fragment, for obtaining a medicine designed to provide a patient with mucosal immunity based on secretion of IgA secretory antibodies, pharmaceutical compositions for the mucous membranes and IgA antibodies.

    Abstract translation: 本发明涉及来自消除细胞的蛋白质，由病毒或免疫细胞感染的细胞或所述蛋白质的无活性片段的用途，所述蛋白质最初是免疫抑制剂和/或具有局部活性的血管生成蛋白质，其中所述性质已被灭活 通过物理和/或化学处理如至少70％，通过基本重组或通过辅助调理来形成，例如甲酰化，羧甲酰化，羧甲基化，马来酰亚胺化或氧化，所述处理保持其被针对所述 蛋白质，并且保留足够的免疫原性，产生中和或阻断所述天然蛋白质的抗体，或使用对应于通过突变而灭活的所述蛋白质的DNA分子或所述非活性片段获得旨在为患者提供基于粘膜免疫的药物 对IgA分泌抗体的分泌，药物组合物 粘膜和IgA抗体的情况。

    Human T-cell lymphotropic virus type II envelope protein and human monoclonal antibodies specific therefor
    15.
    发明授权
    Human T-cell lymphotropic virus type II envelope protein and human monoclonal antibodies specific therefor 有权
    人T细胞淋巴细胞淋巴细胞病毒II型包膜蛋白和特异性的人单克隆抗体

    公开(公告)号：US06270959B1

    公开(公告)日：2001-08-07

    申请号：US09409025

    申请日：1999-09-30

    Applicant: Gregory A. Dekaban ,  Jacqueline Arp ,  Steven Kok Hing Foung

    Inventor： Gregory A. Dekaban ,  Jacqueline Arp ,  Steven Kok Hing Foung

    IPC: C12Q170

    CPC classification number: C07K14/005 ,  C07K16/1036 ,  C07K2317/21 ,  C12N2740/14022 ,  G01N2333/15 ,  Y10S530/806

    Abstract: Isolated and purified envelope protein of HTLV-I is provided devoid of non-envelope protein of HTLV-I and having substantially the same conformation as the envelope protein in native HTLV-I. The protein is produced recombinantly using a dual vaccinia/T7 polymerase system. Non-glycosylated and glycosylated forms of the protein are produced. Glycosylated forms are recognized by antibodies specific for the envelope protein of HTLV-I. Monoclonal antibodies are provided which are specific for the HTLV-I envelope protein and non-binding to HTLV-I envelope protein in denatured form. The HTLV-I envelope protein is cross-reactive with antibodies of HTLV-II and STLV. The envelope protein is useful in diagnosis of infection by HTLV-I and HTLV-II.

    Abstract translation: 提供了HTLV-1的分离和纯化的包膜蛋白，没有HTLV-1的非包膜蛋白，并且具有与天然HTLV-1中的包膜蛋白基本相同的构象。 使用双重牛痘/ T7聚合酶系统重组产生蛋白质。 产生蛋白质的非糖基化和糖基化形式。 糖蛋白形式被HTLV-1的包膜蛋白特异的抗体识别。 提供单克隆抗体，其特异性为HTLV-1包膜蛋白，并且与变性形式的HTLV-1包膜蛋白不结合。 HTLV-1包膜蛋白与HTLV-II和STLV的抗体具有交叉反应性。 包膜蛋白可用于HTLV-I和HTLV-II感染的诊断。

    Polypeptides and antibodies for diagnosing and treating seminoma
    16.
    发明授权
    Polypeptides and antibodies for diagnosing and treating seminoma 失效
    用于诊断和治疗精原细胞瘤的多肽和抗体

    公开(公告)号：US5858723A

    公开(公告)日：1999-01-12

    申请号：US567336

    申请日：1995-12-05

    Applicant: Nikolaus Mueller-Lantzsch ,  Marlies Sauter

    Inventor： Nikolaus Mueller-Lantzsch ,  Marlies Sauter

    IPC: A61K38/00 ,  C07K14/15 ,  C07K16/10 ,  C12P21/06 ,  C12P21/08

    CPC classification number: C07K14/005 ,  C07K16/1036 ,  A61K38/00 ,  C12N2710/14143 ,  C12N2740/10022

    Abstract: Polypeptides are disclosed that are useful for diagnosing seminoma. The polypeptides have a sequence that corresponds to the amino acid sequence of the human endogenous retrovirus K10 (HERV-K10). Also disclosed are recombinant human endogenous retrovirus K10 (HERV-K10) env and gag polypeptides that are synthesized using genetic engineering techniques, constructs and processes for producing the recombinant polypeptides, and an assay for detecting the presence of antibodies specific for HERV-K10 env and/or gag polypeptides in human bodily fluids.

    Abstract translation: 公开了可用于诊断精原细胞瘤的多肽。 多肽具有对应于人内源性逆转录病毒K10（HERV-K10）的氨基酸序列的序列。 还公开了使用遗传工程技术，用于产生重组多肽的构建体和方法合成的重组人内源性逆转录病毒K10（HERV-K10）env和gag多肽，以及用于检测HERV-K10 env特异性抗体的存在的测定法， /或gag多肽在人体液中。

    Viral clearance by low pH hold
    20.
    发明授权
    Viral clearance by low pH hold 有权

    公开(公告)号：US12077782B2

    公开(公告)日：2024-09-03

    申请号：US17317602

    申请日：2021-05-11

    Applicant: Regeneron Pharmaceuticals, Inc.

    Inventor： Jena Daya ,  Valerie Ann Cusick ,  John Mattila

    IPC: C12N7/00 ,  C07K1/14 ,  C07K16/10

    CPC classification number: C12N7/00 ,  C07K1/14 ,  C07K16/1036 ,  C12N2740/13063

    Abstract: Methods for viral clearance using low pH hold based on a statistical design of experiment are provided. Several factors are evaluated to characterize the impacts of a low pH hold step for virus inactivation, including the factors of pH conditions, conductivity conditions, protein type, temperature, acid titrant, spike timing, and post-spike filtration. In addition to the effect of pH on virus inactivation, an increase in ionic strength through manipulating the conductivity can be a key component that influences virus inactivation kinetics.

Patent Agency Ranking